The Effect of Intracameral Carbachol and Epinephrine on Choroidal Thickness

Sponsor
T.C. ORDU ÜNİVERSİTESİ (Other)
Overall Status
Completed
CT.gov ID
NCT05225597
Collaborator
(none)
81
1
3
11.9
6.8

Study Details

Study Description

Brief Summary

81 eyes of 81 patients undergoing cataract surgery were included in this prospective interventional study. During cataract surgery, intracameral carbachol was applied to 27 eyes, intracameral epinephrine was administered to 20 eyes and 34 eyes were the control group. Macular choroidal thickness measurement was performed before, 1 day, and 1 week after phacoemulsification surgery in all patients using optical coherence tomography.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Intracameral administration of epinephrine and carbachol during cataract surgery
N/A

Detailed Description

This study consisted of three groups: epinephrine group, carbachol group, and control group. Intracameral carbachol and epinephrine was not used for complication management. In the epinephrine group, 0.2 mL of epinephrine (1:5000 solution) was used immediately after making the clear corneal incision. In the carbachol group, a 0.5 ml dose of 0.01% carbachol solution (Miostat®, Alcon Laboratories, Inc., Fort Worth, TX) was given intracamerally immediately after viscoelastic matter removal following IOL implantation. The control group was given neither epinephrine nor carbachol.

Mydriasis was induced using combined 2.5% phenylephrine and 1.0% tropicamide topical drops before surgery. All surgeries were performed by the same surgeon (HBK) using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. A combination of 1.6% sodium hyaluronate and 4% chondroitin sulfate (ophthalmic viscosurgical device, Discovisc, Alcon Laboratories, Inc.) was used during capsulorhexis in all three groups, and Alcon Infiniti System (Alcon Laboratories Inc.) was used for phacoemulsification. A continuous curvilinear capsulorhexis of 4.5-5.5 mm was created. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated in irrigation/aspiration mode. Before implanting a one-piece foldable hydrophobic acrylic IOL into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions. Topical moxifloxacin, nepafenac, and prednisolone acetate eye drops were given to all patients six times a day for the first week. Prednisolone acetate was then reduced and discontinued 4 weeks after the operation.

Study Design

Study Type:
Interventional
Actual Enrollment :
81 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This study consisted of three groups: epinephrine group, carbachol group, and control group.This study consisted of three groups: epinephrine group, carbachol group, and control group.
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Participants were unaware of the group in which they were assigned. The person evaluating the results did not know which result belonged to which group.
Primary Purpose:
Treatment
Official Title:
The Effect of Intracameral Carbachol and Epinephrine Use on Choroidal Thickness After Uncomplicated Phacoemulsification
Actual Study Start Date :
Jan 1, 2021
Actual Primary Completion Date :
Aug 30, 2021
Actual Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: epinephrine

In the epinephrine group, 0.2 mL of epinephrine (1:5000 solution) was used immediately after making the clear corneal incision during cataract surgery

Procedure: Intracameral administration of epinephrine and carbachol during cataract surgery
All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.

Active Comparator: carbachol

In the carbachol group, a 0.5 ml dose of 0.01% carbachol solution (Miostat®, Alcon Laboratories, Inc., Fort Worth, TX) was given intracamerally immediately after viscoelastic matter removal following IOL implantation

Procedure: Intracameral administration of epinephrine and carbachol during cataract surgery
All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.

No Intervention: control

The control group was given neither epinephrine nor carbachol. Standard cataract surgery was performed

Outcome Measures

Primary Outcome Measures

  1. choroidal thickness(CT) [preoperatively, on postoperative day 1, and in postoperative week 1]

    CT measurement was performed using a Cirrus HD(high definition) 500 spectral OCT (optical coherence tomography) platform (Carl Zeiss Meditec, Dublin, California, USA). Subfoveal, nasal, temporal, lower choroidal thickness, and upper choroidal thickness were measured manually by two blinded observers with 0.5-mm intervals in vertical and horizontal sections having a length of 4 mm. The distance between the outer hyper-reflective border of the retinal pigment epithelium and the inner scleral surface was considered. Average data obtained by two observers were used in statistical analysis.

Secondary Outcome Measures

  1. intraocular pressure [before, 1 day, and 1 week after surgery]

    Intraocular pressure was measured in all patients using a non-contact tonometer.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • over 18 years old

  • patients with cataracts

Exclusion Criteria:
  • hypertension and diabetes

  • ocular problems such as uveitis, glaucoma, amblyopia

  • maculopathy, retinal dystrophy

  • any previous ocular surgery

  • eye trauma

  • congenital cataracts

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ordu University Ordu ABD Dışında Turkey 52200

Sponsors and Collaborators

  • T.C. ORDU ÜNİVERSİTESİ

Investigators

  • Principal Investigator: Hasan B Kaptı, MD, T.C. ORDU ÜNİVERSİTESİ

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hasan Burhanettin Kapti, Principal Investigator, T.C. ORDU ÜNİVERSİTESİ
ClinicalTrials.gov Identifier:
NCT05225597
Other Study ID Numbers:
  • PANTONE 287 C
First Posted:
Feb 4, 2022
Last Update Posted:
Feb 4, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hasan Burhanettin Kapti, Principal Investigator, T.C. ORDU ÜNİVERSİTESİ
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 4, 2022